Continuous Glucose Monitors Help Type 1 Diabetics Finish Marathons
A small study suggests that with continuous glucose monitoring, people with type 1 diabetes can safely complete marathon-distance races.
New research scheduled for presentation at the European Association for the Study of Diabetes (EASD) annual meeting in Milan suggests that continuous glucose monitoring (CGM) can make marathon running safe for people with type 1 diabetes. The small study focused on participants who used CGM devices to track their glucose levels in real time while completing a full marathon.
The findings indicate that CGM technology helps runners with type 1 diabetes anticipate and respond to glucose fluctuations during intense, prolonged physical activity. This real-time feedback appears to reduce the risk of dangerous hypoglycemia or hyperglycemia, allowing athletes to maintain stable blood sugar levels throughout the race.
While the study is limited in scale, it adds practical evidence to a field where anecdotal experience often outpaces clinical data. The researchers are expected to present detailed glucose profiles and outcomes at the conference, which runs from September 28 to October 2. For now, the takeaway is that marathon participation is not inherently off-limits for people with type 1 diabetes, provided they have the right monitoring tools and management strategies in place.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.